Gabapentin for spasticity: A randomized, double-blind, placebo-controlled trial;Efectividad de la gabapentina en el tratamiento de la espasticidad: Estudio aleatorizado a doble ciego y controlado con placebo

Medicina Clinica

Volumn 124, Issue 3, 2005, Pages 81-85

  Formica, Alessandro ^a   Verger, Katia ^b   Sol, Josep M ^c   Morralla, Claudia ^d  

^a Hospital Nuestra Senora de Aranzazu   (Spain)

^b Programa de Investigación Clínica   (Spain)

^c PFIZER INC   (United States)

^d Fundacion Institut Catala de Farmacologia   (Spain)

Author keywords

Clinical trial; Gabapentin; Spasticity; Upper motoneuron

Indexed keywords

GABAPENTIN; PLACEBO;

ADULT; AGED; ARTICLE; ASHWORTH SCALE SCORE; ASTHENIA; ATAXIA; BARTHEL INDEX; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; ERYTHEMA MULTIFORME; FEMALE; GAIT; HEADACHE; HOFFMANN REFLEX; HOFFMANN REFLEX TO M WAVE AMPLITUDE RATIO; HUMAN; MALE; MOTOR NEURON DISEASE; PILOT STUDY; PRURITUS; PYRAMIDAL SIGN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM; SOMNOLENCE; SPASM FREQUENCY SCALE; SPASTICITY; TREATMENT OUTCOME;

EID: 14344263178     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13070862     Document Type: Article

References (30)

1. Lance JW. Symposium synopsis. En: Feldman RG, Young RR, Koella WP, editors. Spasticity: disorder motor control. Chicago: Year Book Medical Publishers; 1980. p. 485-94.
2. Davidoff RA. Antispasticity drugs: mechanism of action. Ann Neurol. 1985;17:107-16.
3. Taricco M, Adone R, Pagliacci C, Telaro E. Pharmacological interventions for spasticity following spinal cord injury. Cochrane Database Syst Rev. 2000;2:CD001131.
4. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs. 2000;59:487-95.
5. Gelber DA, Jozefczyk PB. Therapeutics in the management of spasticity. Neurorehabil Neural Repair. 1999;13:5-14.
6. Taylor CP. Mechanism of action of new anti-epileptic drugs. En: Chadwick D, editor. New trends in epilepsy management. London: Royal Society of Medicine Services; 1993. p. 13-40.
7. Chadwick D, Anhut H, Greiner MJ, Alexander J, Murray GH, Garofalo EA, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. Neurology. 1998;51:1282-8.
8. UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet. 1990;335:1114-7.
9. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology. 1993;43:2292-8.
10. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia. 1994;35:795-801.
11. Taylor CP, Gee NS, Su TZ, Kocsis JD, Welty DF, Brown JP, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res. 1998;29:233-49.
12. Chizh BA, Scheede M, Schultz H. Antinociception and (R,S)-alpha-amino-3- hydroxy-5-methyl-4-isoxazole propionic acid antagonism by gabapentin in the rat spinal cord in vivo. Naunyn-Schmiedeberg's Arch Pharmacol. 2000;362:197-200.
13. Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Rehabil. 1997;78:521-4.
14. Gruenthal M, Mueller M, Olson WM, Priebe MM, Sherwood AM, Olson WH. Gabapentin for the treatment of spasticity in patients with spinal cord injury. Spinal Cord. 1997;35:686-9.
15. Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: a quantitative study. Spinal Cord. 1997;35:171-5.
16. Cutter N, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81:164-9.
17. McLean MJ. Gabapentin. Epilepsia. 1995;36 Suppl 2:S73-86.
18. Browne T. Efficacy and safety of gabapentin. En: Chadwick D, editor. New trends in epilepsy management. London: Royal Society of Medicine Services; 1993. p. 47-58.
19. Neurontin® [prospecto]. Morris Plains: Parke-Davis: 1998.
20. Ashworth B. Preliminary trial of carisprodol in multiple sclerosis. Practitioner. 1964;192:540-2.
21. Penn RD, Savoy SM, Corcos D, Latash M, Gottlieb G, Parke B, et al. Intrathecal baclofen for severe spinal spasticity. N Engl J Med. 1989: 320:1517-54.
22. Greene WB, Heckman JD, editors. The clinical measurement of joint motion. Rosemont: American Academy of Orthopaedic Surgeons; 1994.
23. Mahoney Fl, Barthel DW. Functional evaluation: the Barthel Index. Maryland State Med J. 1965; 14:61-5.
24. Delwaide PJ. Human reflex studies for understanding the motor system. Phys Med Rehabil Clin North Am. 1993;4:669-86.
25. Nance PW, Bugaresti J, Shellemberger K, Sheremata W, Martínez- Arizala A. Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. Neurology. 1994; 44 Suppl 9:44-52.
26. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology. 1994; 44 Suppl 9:34-43.
27. Wallace MD. Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology. 1994;44 Suppl 9:60-9.
28. Delwaide PJ, Pennisi G. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity. Neurology. 1994; 44 Suppl 9:21-8.
29. Beydoun A, Fakhoury T, Nasreddine W, AbouKhalil B. Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy. Epilepsia. 1998;39:188-93.
30. Morello CM, Leckband SG, Stoner CP, Moorhouse DF, Sahagian GA. Randomized double-blind study comparing the efficacy of gabapentin with amitryptiline on diabetic peripheral neuropathy pain. Arch Intern Med. 1999;159:1931-7. 86-92